{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06005493",
            "orgStudyIdInfo": {
                "id": "D9750C00001"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-000154-20",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "AstraZeneca",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors",
            "officialTitle": "A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T Cell-engaging Bispecific Antibody That Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants With Advanced or Metastatic Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-in-adult-participants-with-advanced-or-metastatic-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-07-11",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-12-11",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-12-11",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-06-16",
            "studyFirstSubmitQcDate": "2023-08-17",
            "studyFirstPostDateStruct": {
                "date": "2023-08-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-25",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "AstraZeneca",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.",
            "detailedDescription": "This is a first-time in human, modular Phase I/II, open-label multicentre study of AZD5863 monotherapy administered intravenously (Module 1), or AZD5863 monotherapy administered subcutaneously (Module 2) in patients with advanced or metastatic solid tumors. Each module contains dose-escalation (Part A) and dose-expansion (Part B)."
        },
        "conditionsModule": {
            "conditions": [
                "Gastric Cancer",
                "Gastro-esophageal Junction Cancer",
                "Pancreatic Ductal Adenocarcinoma",
                "Esophageal Adenocarcinoma"
            ],
            "keywords": [
                "CLDN18.2 / Claudin 18.2",
                "CD3",
                "T cell-engaging bi-specific antibody",
                "Gastric cancer",
                "Gastro-esophageal junction cancer",
                "Pancreatic ductal adenocarcinoma",
                "Solid tumors",
                "AZD5863"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "The study consists of individual modules each evaluating the safety and tolerability of AZD5863 dosed as monotherapy:\n\n* Module 1: AZD5863 intravenous administration\n* Module 2: AZD5863 subcutaneous administration\n\nModules 1 and 2 each consist of two parts: Part A, Dose Escalation and Part B, Dose Expansion.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 200,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Module 1: AZD5863 Monotherapy Intravenous (IV)",
                    "type": "EXPERIMENTAL",
                    "description": "Module 1: AZD5863 Intravenous (IV) Monotherapy",
                    "interventionNames": [
                        "Drug: AZD5863"
                    ]
                },
                {
                    "label": "Module 2: AZD5863 Monotherapy Subcutaneous (SC)",
                    "type": "EXPERIMENTAL",
                    "description": "Module 2: AZD5863 Subcutaneous (SC) Monotherapy",
                    "interventionNames": [
                        "Drug: AZD5863"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "AZD5863",
                    "description": "T cell-engaging bi-specific antibody that targets CLDN18.2 (Claudin18.2) on tumor cells and CD3 on T cells",
                    "armGroupLabels": [
                        "Module 1: AZD5863 Monotherapy Intravenous (IV)",
                        "Module 2: AZD5863 Monotherapy Subcutaneous (SC)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "The number of patients with adverse events",
                    "description": "Number of patients with adverse events by system organ class and preferred term",
                    "timeFrame": "From first dose of study drug up to 90 days post last dose and prior to start of subsequent anticancer therapy"
                },
                {
                    "measure": "The number of patients with adverse events of special interest",
                    "description": "Number of patients with adverse events of special interest by system organ class and preferred term",
                    "timeFrame": "From first dose of study drug up to 90 days post last dose and prior to start of subsequent anticancer therapy"
                },
                {
                    "measure": "The number of patients with dose-limiting toxicity (DLT), as defined in the protocol.",
                    "description": "A DLT is a toxicity as defined in the protocol that occurs from the first dose of study drug up to and including the planned end of Cycle 1 (the DLT assessment period) that is assessed as unrelated to the disease or disease-related processes under investigation.",
                    "timeFrame": "From first dose of study drug until the end of Cycle 1"
                },
                {
                    "measure": "The number of patients with serious adverse events",
                    "description": "Number of patients with serious adverse events by system organ class and preferred term",
                    "timeFrame": "From first dose of study drug up to 90 days post last dose and prior to start of subsequent anticancer therapy"
                },
                {
                    "measure": "Objective Response Rate (ORR)",
                    "description": "The percentage of patients with a confirmed investigator assessed complete or partial response according to response criteria in solid tumours (RECIST 1.1). Dose expansion only.",
                    "timeFrame": "From first dose of study drug to progressive disease or death in the absence of disease progression (approx. 2 years)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Objective Response Rate (ORR)",
                    "description": "The percentage of patients with a confirmed investigator assessed complete or partial response according to response criteria in solid tumours (RECIST 1.1). Dose escalation only.",
                    "timeFrame": "From first dose of study drug to progressive disease or death in the absence of disease progression (approx. 2 years)"
                },
                {
                    "measure": "Disease Control Rate (DCR)",
                    "description": "Percentage of patients with confirmed complete or partial response or having stable disease maintained for \\>= 11 weeks from first dose, according to response criteria in solid tumours (RECIST 1.1).",
                    "timeFrame": "From first dose of study drug to progressive disease or death in the absence of disease progression (approx. 2 years)"
                },
                {
                    "measure": "Duration of response (DoR)",
                    "description": "The time from the date of first response until date of disease progression or death in the absence of disease progression, according to response criteria in solid tumours (RECIST 1.1).",
                    "timeFrame": "From the first documented response to progressive disease or death in the absence of disease progression (approx. 2 years)"
                },
                {
                    "measure": "Progression free Survival (PFS)",
                    "description": "The time from the start of study treatment/date of randomization until RECIST 1.1 defined disease progression or death in the absence of disease progression.",
                    "timeFrame": "From the start of study treatment/date of randomization to progressive disease or death in the absence of disease progression (approx. 2 years)"
                },
                {
                    "measure": "Overall Survival (OS)",
                    "description": "The time from the start of study treatment/date of randomization until death due to any cause.",
                    "timeFrame": "From the start of study treatment/date of randomization to death (to be followed-up for approx. 2 years)"
                },
                {
                    "measure": "Pharmacokinetics of AZD5863: Maximum plasma concentration of the study drug (Cmax)",
                    "description": "Maximum observed plasma concentration of the study drug",
                    "timeFrame": "From the first dose of study intervention, at predefined intervals throughout the study (approx. 2 years)"
                },
                {
                    "measure": "Pharmacokinetics of AZD5863: Area Under the concentration-time curve (AUC)",
                    "description": "Area under the plasma concentration-time curve",
                    "timeFrame": "From the first dose of study intervention, at predefined intervals throughout the study (approx. 2 years)"
                },
                {
                    "measure": "Pharmacokinetics of AZD5863: Clearance",
                    "description": "A pharmacokinetic measurement of the volume of plasma from which the study drug is completely removed per unit time.",
                    "timeFrame": "From the first dose of study intervention, at predefined intervals throughout the study (approx. 2 years)"
                },
                {
                    "measure": "Pharmacokinetics of AZD5863: Terminal elimination half-life (t 1/2)",
                    "description": "Terminal elimination half life.",
                    "timeFrame": "From the first dose of study intervention, at predefined intervals throughout the study (approx. 2 years)"
                },
                {
                    "measure": "Immunogenicity of AZD5863",
                    "description": "The number and percentage of participants who develop anti-drug antibodies (ADAs) measured in serum",
                    "timeFrame": "From the first dose of study intervention, at predefined intervals throughout the study (approx. 2 years)"
                },
                {
                    "measure": "Preliminary antitumor activity with target expression pre- and post-delivery of AZD5863",
                    "description": "Measure CLDN18.2 expression (IHC) in baseline and/or on-treatment tumor biopsies and correlate with clinical outcome",
                    "timeFrame": "From time of Informed consent, at predefined intervals (including screening, on-treatment or end of treatment) throughout the study (over approx. 2 years)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Age \u2265 18 at the time of signing the informed consent\n* Histologically confirmed diagnosis of adenocarcinoma of the stomach, gastro-esophageal junction, esophagus, or pancreas\n* Must have at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\n* Must show positive CLDN18.2 expression in tumor cells as determined by central immunohistochemistry (IHC)\n* Eastern Cooperative Oncology Group Performance status (ECOG PS): 0-1 at screening\n* Predicted life expectancy of \u2265 12 weeks\n* Adequate organ and bone marrow function measured within 28 days prior to first dose as defined by the protocol\n* Contraceptive use by men or women should be consistent with local regulations, as defined by the protocol\n* Must have received at least one prior line of systemic therapy in the advanced/metastatic setting\n\nKey Exclusion Criteria:\n\n* Unresolved toxicity from prior anticancer therapy of Common Terminology Criteria for Adverse Events (CTCAE) Grade \u2265 2 except for those defined by the protocol\n* Participant experienced unacceptable cytokine release syndrome (CRS) or Immune Effector Cell Associated Neurotoxicity (ICANS) following prior T cell engagers (TCE) or chimeric antigen receptor T (CAR-T) cell therapy\n* Previous history of hemophagocytic lymphohistiocytosis (HLH) / macrophage activation syndrome (MAS)\n* Active or prior documented autoimmune or inflammatory disorders within 3 years of start of treatment\n* central nervous system (CNS) metastases or CNS pathology, as defined by the protocol, within 3 months prior to consent\n* Infectious disease including active human immunodeficiency virus (HIV), active hepatitis B/C, uncontrolled infection with EBV, uncontrolled active systemic fungal, bacterial or other infection\n* Cardiac conditions as defined by the protocol\n* History of thromboembolic event within the past 3 months prior to the scheduled first dose of study intervention\n* Participant requires chronic immunosuppressive therapy\n* Participants on anticoagulation therapy",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "AstraZeneca Clinical Study Information Center",
                    "role": "CONTACT",
                    "phone": "1-877-240-9479",
                    "email": "information.center@astrazeneca.com"
                }
            ],
            "locations": [
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Jacksonville",
                    "state": "Florida",
                    "zip": "32224",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 30.33218,
                        "lon": -81.65565
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55905",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 44.02163,
                        "lon": -92.4699
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "WITHDRAWN",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Beijing",
                    "zip": "100142",
                    "country": "China",
                    "geoPoint": {
                        "lat": 39.9075,
                        "lon": 116.39723
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Beijing",
                    "zip": "101199",
                    "country": "China",
                    "geoPoint": {
                        "lat": 39.9075,
                        "lon": 116.39723
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Shandong",
                    "country": "China"
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Chuo-ku",
                    "zip": "104-0045",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.57779,
                        "lon": 139.71685
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Kashiwa",
                    "zip": "227-8577",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.86224,
                        "lon": 139.97732
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Koto-ku",
                    "zip": "135-8550",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.66667,
                        "lon": 139.81718
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "03080",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "03722",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "05505",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "06351",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Amsterdam",
                    "zip": "1081 HV",
                    "country": "Netherlands",
                    "geoPoint": {
                        "lat": 52.37403,
                        "lon": 4.88969
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Groningen",
                    "zip": "9713 GZ",
                    "country": "Netherlands",
                    "geoPoint": {
                        "lat": 53.21917,
                        "lon": 6.56667
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Rotterdam",
                    "zip": "3015 GD",
                    "country": "Netherlands",
                    "geoPoint": {
                        "lat": 51.9225,
                        "lon": 4.47917
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Kaohsiung",
                    "zip": "80756",
                    "country": "Taiwan",
                    "geoPoint": {
                        "lat": 22.61626,
                        "lon": 120.31333
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Tainan City",
                    "zip": "70403",
                    "country": "Taiwan",
                    "geoPoint": {
                        "lat": 22.99083,
                        "lon": 120.21333
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Taoyuan",
                    "zip": "00333",
                    "country": "Taiwan",
                    "geoPoint": {
                        "lat": 24.95233,
                        "lon": 121.20193
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Dundee",
                    "zip": "DD1 9SY",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 56.46913,
                        "lon": -2.97489
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "London",
                    "zip": "E1 1BB",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Oxford",
                    "zip": "OX3 7LE",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.75222,
                        "lon": -1.25596
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Wirral",
                    "zip": "CH63 4JY",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 53.37616,
                        "lon": -3.10501
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure\n\n\"Yes\", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP"
            ],
            "timeFrame": "AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure",
            "accessCriteria": "When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.",
            "url": "https://astrazenecagroup-dt.pharmacm.com/DT/Home"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                },
                {
                    "id": "D000013274",
                    "term": "Stomach Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000005770",
                    "term": "Gastrointestinal Neoplasms"
                },
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000005767",
                    "term": "Gastrointestinal Diseases"
                },
                {
                    "id": "D000013272",
                    "term": "Stomach Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "asFound": "Adenocarcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16064",
                    "name": "Stomach Neoplasms",
                    "asFound": "Gastric Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M16062",
                    "name": "Stomach Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T5486",
                    "name": "Stomach Cancer",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M20194",
                    "name": "Antibodies, Bispecific",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}